Method of treatment of pain by administration of a CCL17 specific antibody

Patent metadata

Field	Value
Publication number	US-9988445-B2
Application number	US-201414916141-A
Country	US
Kind code	B2
Filing date	Sep 2, 2014
Priority date	Sep 2, 2013
Publication date	Jun 5, 2018
Grant date	Jun 5, 2018

Abstract

A protocol for pain management includes a pharmaceutical composition and its use in ameliorating the sensation of pain. The protocol includes the use of a CCL17 signaling antagonist alone or in combination with another analgesic compound to treat pain associated with inflammatory conditions. The CCL17 signaling antagonist includes an antibody or antigen-binding derivative thereof which binds to CCL17 or its receptor.

First claim

The invention claimed is:

1. A method for inducing an analgesic response to pain in a subject in need thereof, said method comprising administering to said subject of an amount of a CCL17 specific antibody effective in reducing the level of or otherwise ameliorating the sensation of pain.

2. The method of claim 1 further comprising administering another analgesic compound.

3. The method of claim 2 wherein the other analgesic compound is selected from the group consisting of an NSAID, steroid, an anti-inflammatory cytokine, an N-type calcium channel antagonist, an antibody to an inflammatory cytokine, a narcotic, an anticonvulsant and a local anesthetic.

4. The method of claim 1 , wherein the pain is neuropathic pain.

5. The method of claim 1 , wherein the pain is inflammatory pain.

6. The method of claim 5 , wherein, the inflammatory pain is associated with osteoarthritis.

7. The method of claim 5 wherein the inflammatory pain is associated with rheumatoid arthritis.

8. The method of claim 1 wherein the CCL17 specific antibody is administered in an amount of about 0.5 μg to about 20 mg per kg of body weight.

9. The method of claim 1 wherein the subject is a human.

10. A method of treating pain associated with a disease or physiological condition in a subject, said method comprising administering to said subject an effective amount of a CCL17 specific antibody.

11. The method of claim 10 wherein the subject is a human.

12. The method of claim 10 wherein the pain is neuropathic pain or inflammatory pain.

13. The method of claim 12 wherein the pain is associated with osteoarthritis.

14. The method of claim 13 wherein the pain is associated with rheumatoid arthritis.

Assignees

• Univ Melbourne

Inventors

• Cook Andrew
• Hamilton John
• Achuthan Adrian
• Lacey Derek

Classifications

• A61P25/04

  Centrally acting analgesics, e.g. opioids · CPC title

• A61P25/02

  for peripheral neuropathies · CPC title

• A61K39/3955

  against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title

• C07K16/24 Primary

  against cytokines, lymphokines or interferons · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title